G
Geoffrey O. Littlejohn
Researcher at Monash University, Clayton campus
Publications - 219
Citations - 6175
Geoffrey O. Littlejohn is an academic researcher from Monash University, Clayton campus. The author has contributed to research in topics: Fibromyalgia & Rheumatoid arthritis. The author has an hindex of 38, co-authored 210 publications receiving 5476 citations. Previous affiliations of Geoffrey O. Littlejohn include University Health Network & Wellesley Institute.
Papers
More filters
Journal ArticleDOI
Nociplastic pain: towards an understanding of prevalent pain conditions
Mary Ann Fitzcharles,Steven P. Cohen,Steven P. Cohen,Daniel J. Clauw,Geoffrey O. Littlejohn,Chie Usui,Winfried Häuser +6 more
TL;DR: Nociplastic pain this paper is a third category of pain that is mechanistically distinct from nociceptive pain, which is caused by ongoing inflammation and damage of tissues, and neuropathic pain, caused by nerve damage.
Journal ArticleDOI
Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome
TL;DR: The results indicate that patients with FS exhibit a significant reduction in heat pain threshold when tested on the dorsal surface of the hand and a greater activation of central nervous system (CNS) pathways following noxious input.
Journal ArticleDOI
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Christopher J. Hawkey,A M Kahan,K Steinbruck,C Alegre,E Baumelou,B Begaud,Jan Dequeker,H Isomaki,Geoffrey O. Littlejohn,J Mau,S Papazoglou +10 more
TL;DR: The MELISSA trial confirms earlier studies suggesting that meloxicam has a significantly improved GI tolerability profile in comparison with other NSAIDs, including diclofenac, and provides support for the hypothesis that selective inhibition of COX-2 relative toCOX-1 might be an effective approach towards improved NSAID therapy.
Journal ArticleDOI
Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome.
TL;DR: These results suggest that there is a diffuse change in pain modulation in fibromyalgia, as hypothesized, but the tender point is still clinically useful.
Journal ArticleDOI
Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
Jan Dequeker,Christopher J. Hawkey,A M Kahan,K Steinbruck,C Alegre,E Baumelou,B Begaud,H Isomaki,Geoffrey O. Littlejohn,J Mau,S Papazoglou +10 more
TL;DR: The outcome of SELECT is consistent with that of the large-scale clinical trial of similar design and size which compared 7.5 mg meloxicam with 100 mg diclofenac in patients with osteoarthritis, and with a previous global analysis of the safety ofmeloxicam.